Autopsy report · NCT03165721
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Cause of deathSlow enrollment
“Study closed to enrollment due to low accrual.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 6 months before it stopped.
- 9 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; Pheochromocytoma
- Interventions
- SGI-110 (guadecitabine)
- Participants
- 9
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
“The study was closed to enrollment due to slow accrual.” - Salvage Cryotherapy in Recurrent Prostate Cancer
“Study was ended due to low enrollment” - Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
“Study closed due to slow enrollment.” - Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
“Study closed before total enrollment met.” - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
“Study was closed to low accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.